Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Cabozantinib (Cabometyx) was first approved by the FDA in 2012. It is a non‑specific tyrosine kinase inhibitor that exerts antitumor activity by selectively inhibiting the MET, VEG···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：200
On March 26, 2025, Exelixis, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Cabometyx (cabozantinib) for the treatment of two patient populations:Adul···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：229
Cabozantinib is a small-molecule multi-targeted tyrosine kinase inhibitor developed by Exelixis, Inc. (USA). It was first approved by the FDA in November 2012 for progressive metas···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：177
Cabozantinib is a broad‑spectrum multi‑targeted anticancer drug that inhibits at least 9 targets, including MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT.Side Effects Requiring Im···【more】
Article source：Captain MedicineRelease date：2026-03-20Recommended：170
Lorlatinib is a novel, third-generation, small-molecule dual ALK/ROS1 inhibitor developed by Pfizer Inc., USA.Side Effects of Lorlatinib Requiring Immediate Medical AttentionSeek i···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：260
Lorlatinib was first approved in Japan in September 2018, followed by approval from the U.S. Food and Drug Administration (FDA) in November of the same year, and in the European Un···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：327
Dabrafenib is a selective BRAF serine-threonine kinase inhibitor that exerts antitumor effects by specifically targeting the BRAF V600E/V600K mutation site. Developed by Novartis P···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：238
Dabrafenib is a kinase inhibitor developed by Novartis Pharmaceuticals. It was first approved by the FDA for marketing on May 29, 2013. Dabrafenib inhibits the cell growth of vario···【more】
Article source：Captain MedicineRelease date：2026-03-19Recommended：172
Sparsentan, developed by Travere Therapeutics, is a dual receptor antagonist that significantly reduces proteinuria by simultaneously blocking endothelin type A (ETA) and angiotens···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：231
Sparsentan, developed by Travere Therapeutics, is an endothelin and angiotensin II receptor antagonist. The drug received accelerated approval from the FDA in February 2023 for red···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：267
During treatment with Sparsentan, regular monitoring is required. Follow-up should be conducted before treatment and monthly for the first 12 months, followed by evaluations every ···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：200
Sparsentan is the first dual pathway blocker. Its usage and dosage should be determined based on each patient's specific condition. The recommended starting dose is 200 mg dail···【more】
Article source：Captain MedicineRelease date：2026-03-18Recommended：226
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended：[list:visits]2026-30-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
